Figure 1.
Monitoring strategies and switch criteria.
Table 1.
Characteristics of the population at baseline at beginning of 2015 (adults 15–65 years old).
Figure 2.
Outcomes by monitoring strategy.
Mean over 2015–2025 (except for cost and DALYs where total over this period is given). VL - viral load.
Figure 3.
Breakdown of costs by strategy - total discounted cost 2015–2025, in $million.
See Figure 1 for legend for strategies.
Figure 4.
Incremental costs and DALYs averted for monitoring strategies over 10 years, compared with no monitoring, no second line.
See Figure 1 for legend for strategies.
Figure 5.
One way sensitivity analyses with the following changes from the base scenario (a) poorer adherence profile (b) 20 year time horizon (c) resistance test cost of $15 instead of $30 (d) cost of second line drugs made the same as cost of 1st line (e) initiation of ART at CD4 count below 500 cells/mm3 rather than below 350 cells/mm3 (f) if boosted PI drugs had same potency as other drugs, and risk of resistance accumulation similar to NNRTI.